NOT FDA-APPROVED

Dihexa

A small synthetic peptide derived from angiotensin IV, marketed as a "more potent than BDNF" nootropic. The animal data is interesting. The headline claim needs careful unpacking. Human evidence is essentially nonexistent.

The 30-second read

Dihexa is a small synthetic peptide developed at Washington State University by Dr. Joseph Harding's lab. It's structurally derived from angiotensin IV, a metabolite of the renin-angiotensin system, and was designed to activate the HGF/c-Met pathway, which is involved in synapse formation in the brain. Animal studies in rat models of cognitive impairment showed striking memory improvements. The often-quoted headline, that Dihexa is "millions of times more potent than BDNF", comes from a specific in-vitro spinogenesis assay and isn't a clinical claim. There are essentially no human trials. It's not FDA-approved. The peptide is unusually small and lipophilic enough to be taken orally, which is rare for peptides. The honest framing: interesting biology, near-zero human data, claims that often outrun the evidence.

Why this peptide is on people's radar

Dihexa got into the nootropic conversation through a single striking claim that propagated across podcasts, blogs, and biohacker forums: it's "10 million times more potent than BDNF" at promoting synapse formation. That number is real, it comes from a specific in-vitro spinogenesis assay in the Harding lab's published research, but interpreting it requires care. "More potent than BDNF in a cell-culture spinogenesis assay" is a different claim than "produces 10 million times the cognitive benefit of BDNF in humans." Those got conflated almost immediately as the claim spread.

The biology underneath is genuinely interesting. Angiotensin IV (the natural metabolite Dihexa is derived from) activates an unusual pathway involving HGF (hepatocyte growth factor) and c-Met, with downstream effects on synapse formation, memory consolidation, and neuroplasticity. In rat models of cognitive impairment, including aged rats and rats with amyloid-related deficits. Dihexa restored memory function in some studies. That's the foundation of the nootropic interest.

What's distinctive about Dihexa among research peptides: it's small enough and lipophilic enough to be taken orally, which is rare. Most peptides get destroyed in the stomach. Dihexa is reported to survive oral administration well enough to show effects in animal models. That's part of why it's appeared in nootropic and biohacker contexts, no injection required. As a result, it gets used much more casually than peptides that require subcutaneous administration.

What people are usually trying to do with it

People exploring Dihexa are usually focused on:

Cognitive enhancement, memory, focus, learning capacity
Supporting brain health through age-related decline
Recovery from concussion, traumatic brain injury, or post-concussive symptoms
Adding a "powerful nootropic" to a stack
Following the Harding-lab synaptogenesis story for personal application
Trying an oral peptide rather than injectable

What the science actually shows

Plain-English summary, with the most important caveat first:

Memory restoration in rat models

Multiple studies from the Harding lab show Dihexa restored memory in rat models of cognitive impairment, aged rats, rats with amyloid-related deficits. The animal-model effect is real and reproducible within that lab.1

HGF/c-Met pathway activation

The proposed mechanism, that Dihexa activates HGF binding to c-Met receptors and supports synapse formation, has cellular evidence behind it. The pathway is real and biologically reasonable.2

The "more potent than BDNF" claim

Comes from an in-vitro spinogenesis assay measuring dendritic-spine formation in cultured neurons. In that specific assay, Dihexa was orders of magnitude more effective than BDNF on a per-mole basis. This is a real finding in a narrow context. It is not a claim about clinical effect in humans.3

Oral bioavailability (animal data)

Animal studies suggest Dihexa survives oral administration well enough to produce CNS effects, which is unusual for a peptide. Human pharmacokinetic data does not exist.

What hasn't been demonstrated

Any cognitive benefit in humans. No randomized controlled trials. No published pilot studies in cognitively impaired patients. No long-term safety data. The translational gap from "rat memory model" to "human cognition" hasn't been bridged for Dihexa specifically.

The honest read

What's solid:

The Harding lab's animal studies are real and reproducible within that group. The HGF/c-Met mechanism is biologically plausible. The unusual oral bioavailability for a peptide is genuinely interesting from a drug-design standpoint. There's a real scientific story underneath.

What's still unproven:

Effectively all of the human use case. Zero human trials of meaningful size or rigor exist for Dihexa. The animal-model results have not been independently replicated outside the original research group at scale. Long-term safety, particularly for chronic CNS-active peptide use, isn't characterized.

What's hyped beyond the evidence:

The "10 million times more potent than BDNF" framing as a clinical claim. That number comes from one specific in-vitro spinogenesis assay and has been routinely conflated with "much better than other cognitive enhancers", it isn't that. Theoretical safety concerns also deserve more attention than the marketing gives them: Dihexa's mechanism (synapse formation, neuroplasticity) is exactly the kind of thing that can be problematic in tumor biology and brain conditions where uncontrolled neural growth is a feature, not a benefit. The animal data hasn't tested those concerns adequately.

Things to know if you're looking into it

Oral or sublingual: unlike most peptides, Dihexa is reported to survive oral administration well enough to produce CNS effects. Most research-community use is oral or sublingual rather than injectable.
Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list. No major pharmaceutical company has announced clinical development.
The "BDNF potency" claim is narrow: the eye-catching number is from a specific in-vitro assay, not from human cognitive trials. Anyone using it as the primary reason to take Dihexa is overinterpreting the data.
Theoretical safety considerations are real: a peptide that aggressively promotes synapse formation has obvious theoretical concerns in cancer biology (uncontrolled cell growth) and in conditions like epilepsy or schizophrenia where neuroplasticity changes could be unwelcome. The clinical safety data needed to address those concerns hasn't been generated.
Cognitive issues need evaluation: persistent memory problems, post-concussive symptoms, or cognitive decline warrant proper neurological evaluation before considering experimental peptides.
Healthcare provider involvement: recommended, especially for people with cognitive concerns serious enough to consider Dihexa.
Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

Is Dihexa really 10 million times more potent than BDNF?

In a specific in-vitro spinogenesis assay measuring dendritic-spine formation, yes, that's where the number comes from. Whether that translates into anywhere near that level of clinical benefit in humans is completely unproven. The number is real, the conflation with clinical claims isn't.

Does it actually help cognition?

In rat models of cognitive impairment, repeatedly. In humans, there's no rigorous evidence either way. Anecdotal user reports in nootropic communities are mixed.

Why is it taken orally?

Dihexa is small and lipophilic enough to survive stomach acid and reach the bloodstream, unusual for a peptide. Animal data supports oral activity. Whether human oral pharmacokinetics work as well as the animal data suggests isn't formally characterized.

Is it FDA-approved?

No. Not approved for any indication. Not on the FDA Category 2 list as of 2026.

What about safety concerns?

The theoretical concerns are meaningful: Dihexa's mechanism (synapse formation, neuroplasticity) overlaps with biology that can go wrong in cancer and certain brain conditions. The animal data hasn't tested those concerns, and there's no human safety data. "Safe in healthy adults using it for nootropic purposes" is not an established conclusion.

Is it a "smart drug" like Modafinil?

Different category entirely. Modafinil is a wake-promoting stimulant with FDA approval for narcolepsy and decades of safety data. Dihexa is an experimental compound with no human trials. The comparison flatters Dihexa more than the evidence supports.

Are there interactions with other medications?

Formal interaction studies don't exist. Dihexa's mechanism touches HGF/c-Met signaling, which is involved in many tissues. People on cancer medications, antidepressants, or any drug with neurological effects should involve a clinician.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Not currently on the FDA Category 2 list. No major pharmaceutical company has announced a clinical development program. No human trials are registered on ClinicalTrials.gov as of this date. Status updates land here when they happen.

Want to go deeper? Mechanism, HGF/c-Met pathway detail, dosing, side effects, and references.

Background and discovery

Dihexa (chemical name N-Hexanoic-Tyr-Ile-6-Aminohexanoic Amide) is a synthetic peptide derivative of angiotensin IV, a metabolite of the renin-angiotensin system. It was developed by Joseph Harding and colleagues at Washington State University as part of research into the cognitive effects of angiotensin IV and the HGF/c-Met pathway. The compound's small size and lipophilic structure give it unusual properties for a peptide, including oral bioavailability and brain penetration.

Mechanism of action

HGF/c-Met pathway activation

Dihexa is proposed to facilitate binding of hepatocyte growth factor (HGF) to its receptor c-Met, particularly in the central nervous system. HGF/c-Met signaling supports synapse formation, neuroplasticity, and neuronal survival.

Dendritic spine formation (spinogenesis)

In cultured hippocampal neurons, Dihexa induces formation of new dendritic spines, the structural basis of synapse formation. The "10 million times more potent than BDNF" claim comes from comparison in this specific assay.

Memory effects in animal models

Rat models of cognitive impairment (aged rats, scopolamine-impaired rats, amyloid-impaired rats) show restored or improved memory function with Dihexa treatment.

Oral bioavailability and BBB penetration

Dihexa's small size, lipophilicity, and stability give it unusual oral bioavailability for a peptide and the ability to cross the blood-brain barrier in animal models.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision. Dihexa is investigational with essentially no human safety data.

Oral / sublingual (research-community range): 10 to 20 mg daily. Some protocols front-load with higher doses for the first few weeks; others maintain consistent daily dosing.

Treatment duration: typical research-community cycle ranges are 4 to 12 weeks. Long-term continuous use in healthy adults has not been formally characterized.

Side effects and safety profile

Reported in research and community settings (uncommon overall):

Headache (occasional, mild)
Mild GI upset (uncommon)
Sleep disturbance (uncommon)
Anxiety or restlessness (uncommon, dose-dependent)

Theoretical safety concerns that haven't been adequately tested:

HGF/c-Met signaling is involved in tumor biology, uncontrolled c-Met activation is a feature of multiple cancers. Avoid in active malignancy or strong cancer family history.
Neuroplasticity changes could theoretically affect conditions like epilepsy, bipolar disorder, schizophrenia, where excess plasticity is unwelcome.
Long-term effects of regular synapse-formation stimulation in healthy adult brains are unknown.

References

McCoy AT, Benoist CC, Wright JW, et al. (2013). "Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents." J Pharmacol Exp Ther, 344(1), 141–154. PubMed
Benoist CC, Wright JW, Zhu M, et al. (2011). "Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs." J Pharmacol Exp Ther, 339(1), 35–44. PubMed
Wright JW, Harding JW. (2015). "The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease." J Alzheimers Dis, 47(2), 295–303. PubMed
Wright JW, Kawas LH, Harding JW. (2015). "The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases." Prog Neurobiol, 125, 26–46. PubMed
Harding JW, Wright JW, Swanson GN, et al. (1994). "AT4 receptors: specificity and distribution." Kidney Int, 46(6), 1510–1512. PubMed

For educational and research purposes only. This is not medical advice. Dihexa is not FDA-approved and has essentially no human clinical evidence. Cognitive concerns warrant proper neurological evaluation before considering experimental compounds. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.